Phase II
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
The drug for treatment-resistant depression reportedly demonstrated significant improvement in patients at its highest dose of 25 mg. Here’s more about it.
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Pfizer plans to seek Emergency Use Authorization for an antiviral COVID-19 treatment following an interim analysis of Phase II/III data that show statistically and clinically meaningful results.
Sangamo Therapeutics announced positive preliminary findings from its ongoing Phase I/II STAAR clinical trial in Fabry disease.
CytoDyn announced two separate stories about its drug leronlimab today, one for nonalcoholic steatohepatitis and the other for metastatic triple-negative breast cancer.
An announcement lit up the global grapevine today as Clene Nanomedicine released the results from Phase II of their RESCUE-ALS clinical trial.
This lipid-based system is able to tightly target antigen-presenting cells and thus trigger a rapid, persistent and robust T cell response against various cancers.
PRESS RELEASES